PHARMACEUTICAL EVALUATION OF COMMERCIAL BRANDS OF CEFIXIME 400MG CAPSULES MARKETED IN KARACHI (PAKISTAN)

*Gauhar Shahnaz, Hafiz Muhammad Arshad, * Naqvi Syed Baqir Shyum, Raheela Bano, Mahmood Shoukat and * Muhammad Iyad Naeem

*Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Baqai Institute of Pharmaceutical Sciences, Baqai Medical University, Karachi, Postal code: 75270, Pakistan. Cell # 0300-8962840 Fax: 92-021-9261367

ABSTRACT

The sale and use of substandard drugs is a major health problem in many developing countries where strict drug control legislation does not exist. The study investigates pharmaceutical quality of different brands of cefixime 400mg capsules marketed in Karachi (Pakistan). Compendial standards and government regulations require that all drug products, whether prescription or OTC products, meet strict standards of identity, potency, and purity. Each type of dosage form requires careful study of the physical and chemical properties of drug substances to achieve a stable and effective product. The different brands were subjected to various tests like uniformity of weight, diameter, length, disintegration, dissolution and chemical assays. The susceptibility test of drug was also carried out using agar dilution method along different isolates obtained from health care set ups. All the 6 brands had satisfactory drug content, antimicrobial activity and all passed the USP drug release test. The six brands are physically and chemically equivalent and could be interchanged. The study reinforces the need for constant monitoring of proprietary products of the same generic drugs to ensure quality and consequent efficacy with pharmacoeconomy, which would help in the selection of the most appropriate brand in terms of Pharmacoeconomy and quality.

Keywords: *Cefixime; Comparative evaluation; Physiochemical property; Pharmacoeconomy; Antibiotics; Study of Pharmaceutical quality; Cephalosporin.*

INTRODUCTION

Marketing of poor quality drugs is of concern in developing countries and has been widely reported[1-4]. In some cases, expired drugs have been intentionally given to patients due to economic reasons or lack of adequate drug information and education[4]. In a recent study in Sudan, a number of drugs used in the country such as ergometrine, lignocaine, adrenaline, suxamethonium and ampicillin were shown to degrade rapidly under tropical conditions[1]. The Caribbean Regional Drug Testing Laboratory found that between 10 and 50% of the samples from different countries in the region did not comply with test requirements during 1988-91. Similarly, the Drug Quality Control Laboratory in Daru, Kenya, found that about 45% of the locally manufactured drugs and 31% of those imported during 1983-86 did not meet test requirements[3].

The increase in the number of generic drug products from multiple sources has placed people involved in the delivery of health care in a position of having to select one from among several seemingly equivalent products. For instance, in 1975 approximately 9% of all prescription drugs dispensed in the United States were generic versions[5]. This figure[5] rose to 20% in 1984 and 40% in 1991. Over 80% of the approximately 10,000 prescription drugs available, in 1990, were obtained from more than one source and variable clinical responses were documented due to two or more drug manufacturers who supplied these dosage forms[6]. These variable responses may be due to formulation ingredients employed, methods of handling, packaging and storage and even the rigors of in-process quality control. Thus, there is need to determine their pharmaceutical and therapeutic equivalence in order to ensure interchangeability[7]. However, many developing countries do not have an effective means of monitoring the quality of generic drug products in the market. This results in widespread distribution of substandard and/or counterfeit drug products. It was in view of this fact that the World Health Organization issued guidelines for global standard and requirements for the registration, assessment, marketing, authorization and quality control of generic pharmaceutical products[8]. Preliminary physicochemical assessment of the products is very important and *in vitro* dissolution testing can be a valuable predictor of the *in vivo* bioavailability and bioequivalence of oral solid dosage forms[9].

Cefixime, a broad spectrum, bactericidal, -lactamase stable, third generation cephalosporin, is a semi synthetic first orally active and effective antibiotic[10-11]. Years of extensive investigations on cefixime have

*Correspondence : shahnaz_gauhar@yahoo.com

indicated that it is an excellent orally active antibiotic with similar antibacterial activity and resistance to -lactamase as the third generation parenteral cephalosporins[12-13]. Cefixime has excellent biological properties, displaying potent antibacterial activity against a vide range of Gram-positive bacteria and gram-negative bacteria, highly stable towards -lactamases and long acting efficacy[12]. Memon et al.[14] reported cefixime as a safe, effective, and cheaper oral option for the treatment of multidrug-resistance.

In the present study the physico-chemical equivalence and antimicrobial activity of six different commercial brands of cefixime capsules sourced from retail pharmacies of Karachi was determined using *in vitro* method. This preliminary study is aimed to obtain baseline data towards the establishment of bioequivalence of the capsules.

EXPERIMENTAL
Instrumentation
The analysis of cefixime content in their dosage form was done by a Shimadzu HPLC system, equipped with LC-10 AT VP pump and SPD- 10 a VP UV-VIS detector. Chromatographic system was integrated via Shimadzu model CBM-102 Communication Bus Module to P-III computer loaded with Shimadzu Class-VP software for data acquisition and mathematical calculations. C_{18} Shim–pack CLC–ODS Column (6mmID × 15 cm), protected by octa decyl silane guard column (Pre-column), manual injector fitted with a Loop -20μl.

Analytical balance, dissolution test apparatus (Erweka GmbH), UV spectrophotometer (Parken ELMER; ë-20, Model 1601), disintegration test apparatus (Erweka GmbH, Heusenstamm, Germany), sonicator, pH meter, micropipettes (200 - 1000μl), incubator (Heraeus, Typ B-6, Germany), hot oven (EHRET, D -2800 Breman, Germany), autoclave (OSK 8869-D, Autoclave AC - 220V50HZ), Laminar flow (ESCO), wire loop, burner, test tube holder and vortex.

Materials and reagents
Reference cefixime was a kind gift from Hilton Pharma (Private) Limited. Six different brands of cefixime were obtained from retail pharmacies of Karachi (Pakistan) market. All reagents used were of HPLC grade. Methanol, sodium hydrogen phosphate and ortho-phosphoric acid 85% (Merck, Germany).

Mueller–Hinton broth, Mueller–Hinton agar, standard organisms [*E. coli*, ATCC = 25922; *S. aureus*, ATCC = 25923], clinical isolates (*E. coli, and S.aureus*), dihydrate barium chloride, sulphuric acid, sterile cotton rolls and HPLC grade distilled water were freshly obtained to prepare mobile phase and dilutions.

Chromatographic Condition
The sample solutions were introduced into the system by injector with a 20-μl loop. The flow rate was 1ml/min. Chromatograms were recorded at 288nm.

Spectrophotometeric condition
Base line was adjusted to zero by using blank solvent (0.05M Potassium phosphate buffer). Standard and test sample were analyzed (the observed result was based on three average readings).

PHYSIOCHEMICAL PARAMETERS
Drug cost and quality are the major component of the total cost of the National Health Services (NHS) which is constantly rising. As the resources of the NHS are limited, so it is the need of time to keep eye on the quality and cost of the drugs that are available in the markets. There are a number of companies that manufactures cefixime capsules. The label information of six different brands of capsule are presented in Table 1

Table 1: Label Information of Cefixime Capsule (400mg)

S. #	BRAND NAME	BATCH NO.	MFG. DATE	EXP. DATE	COMPANY NAME
1	CEF-1	4D135	APR 2004	APR 2006	Pham Bio (Pvt) Ltd. Port Qasim Karachi.
2	CEF-2	41133	01-2004	01-2006	Bosch Pharmaceutical (Pvt) Ltd. Karachi
3	CEF-3	41133	10-2004	10-2006	Hilton Pharmaceutical Pvt. Ltd. Karachi
4	CEF-4	04	FEB 2005	02-2007	Zafa Pharmaceutical Laboratories (Pvt) Ltd. Karachi H 5950
5	CEF-5	E4011	06-2004	06-2006	Nabiqas In Industries (Pvt) Ltd. Karachi
6	CEF-6	071	12-2004	12-2006	Tabros Pharmaceutical (Pvt) Ltd. Karachi

Weight variation
The volume and complexity of modern medicines are increasing day by day. The need is to compare the pharmaceutical, chemical and therapeutical efficacy of medicines with their cost. Capsules are the solid dosage forms containing the drug and usually filler(s), enclosed in a hard or soft gelatin shell. The gelatin shell readily ruptures and dissolves following oral administration, and in most cases the drug is released from capsules faster than from tablets[15]. The dose uniformity of tablets/capsules can be determined by weight variation. Weight variation requirements may be applied where the product is a liquid-filled soft capsule, or where the product to be tested contains 50mg or more of a single active ingredient comprising 50% or more, by weight, of the dosage form unit.

Length and diameter
BP-2002[16] introduced a standard for capsules length and diameter to reduce patient confusion over generic equipments. Length and diameters of the capsules were also collected.

Disintegration
Disintegrations are required to break up tablets, capsules and granules into primary powder particles in order to increase surface area of the drugs exposed to gastrointestinal fluids. The disintegration test was carried out by using Erweka ZT 3 Disintegrator. A 1000ml beaker was filled with distilled water (approx. 900ml), equilibrated to 37±0.5ºC. Six capsules from each brand were subjected to the test. Time required for the last capsule to disintegrate was recorded.

Dissolution

During dissolution test the cumulative amount of drug that passed into the solution was studied as a function of time. The test described the rate of release of the drug from the dosage form. Dissolution test was carried out by using an Erweka dissolution instrument. Paddle method (apparatus-2; USP-27)[17] was used at 50 rpm. Potassium phosphate buffer 0.05M (900ml), pH-7.0, was poured into the vessel and equilibrated to 37±0.5 ºC. Six capsules from each brand were tested. 5ml of aliquot was withdrawn at the intervals of 15, 30 and 45 min, and the volumes withdrawn, replaced with fresh dissolution medium. The sample was filtered, using Whatman filter paper and 2ml of filtrate was further diluted as working solution. The absorbance was measured at 288 nm.

Standard Preparation for dissolution

44 mg (on dried basis) of cefixime standard powder was dissolved in 100 ml of 0.05M potassium phosphate buffer (pH-7.0) and the final concentration was made of 8.8µg/ml.

Assay

Analysis of drug potency in capsules comprises the following steps:

Preparation of standard solution for HPLC

100 mg of cefixime standard was weighed and dissolved in 50 ml volumetric flask with few ml of methanol and the volume was made up with mobile phase obtaining concentration equivalent to 0.2mg/ml.

Preparation of Mobile Phase

Mobile phase consisted of 12.5mM KH_2PO_4 buffer solution and methanol (65:35v/v, pH adjusted at 2.75 with 85% orthophosphoric acid). Prior to delivering into the system it was filtered through 0.45µm filter and degassed using a sonicator. The method used for the analysis of cefixime in capsules was first developed and validated[18].

Preparation of Sample Solution

20 capsules were weighed accurately and grinded to a fine powder. 500mg of grinded powder i.e. equivalent to average weight of capsule was transferred to a volumetric flask (250ml), dissolved in mobile phase and shaken for about 10 minutes and then filtered. Filtrate solution was further diluted in the mobile phase and the concentration of working sample solution made equivalent to 0.2mg/ml.

ANTIBACTERIAL ACTIVITY

In the present study the resistance pattern and comparative activities of cefixime standard with different commercial brands (available in the local market) were determined using agar dilution method[19]. The organisms used were:

E.coli (ATCC-25922).
Five isolates of E.coli of different sources.
S. aureus (ATCC - 25923), and.
Five isolates of *S. aureus* of different sources.
Stepwise considerable points were:
1. Preparation of the Mcfarland Standard
2. Preparation of Inoculums
3. Preparation of Antibiotic Stock Solution
Suitable ranges of antibiotic concentrations were selected for the organisms to be tested.
Standard antibiotics powder (Reference powder of cefixime and different brands) weighed accurately for the preparation of stock solutions by using the following formula:

$$W = \frac{1000}{P} \times V \times C$$

Where,
W = Weight of antibiotic to be dissolved in volume (v).
P = Potency given by the manufacturer.
V = Volume required.
C = Final concentration of solution.

After preparing the stock solution, serial dilutions of varying concentrations, usually doubling concentration (0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, and 64 µg/ml), were prepared. Equal volumes of inoculums were added in each.

RESULT

Many drugs that are manufactured in developing countries are implicated to be substandard [20-21]. Price fluctuation in societies where there is no regulatory control has been a severe problem related to the quality of the drug. The variation in the price has been observed from as much as 32 to 55 PKR per unit (Fig.1) while there was no significant variation in the quality of the tested drugs. Hence it may be suggested that the most economic available drug should be used when the pharmaceutical outcomes are promising too. This would lead to more pharmaco-economic practices for the common people in the third world countries like us. Comparative study of various formulations is a pronounced concept used in therapeutic disciplines. It provides understanding in the comparative difference of quality control test / parameters of cefixime and the effect of these differences on the release of drug from the dosage form. The present study made attempt to check the weight variation, diameter, length, disintegration time and dissolution, chemical assay, of the six different brands of cefixime 400mg capsules.

Price Fluctuation

The price fluctuation of the studied brands is depicted in Fig. 1.

Fig. 1: Price fluctuation among different brands of cefixime available in local market of Karachi

Weight variation

Table 2 shows weight variation of capsules with their standard deviation, average diameter of six brands with their standard deviation and average length of the different brands of cefixime capsules. The Fig.2 represents the variation in the length of the capsule shell size that plays an important role in the compliance of patients. It reveals that results are highly significant with the limits given ±7.5%[16].

Table 2. Physical parameters of six different brands of cefixime 400mg capsules

| Brand a	ra an	ra an	d a	r ra an	n
	518.75 ± 11.51	7.3± 3B	3.3 ± 3B		
	87.5 ± 3B	7.5 ± 3B	3.3± 3I8		
	38.5 ± 11.85	7.3± 3B3	3.55 ± 3B		
	578.3± 3.3	7.3 ± 3B	3.185 ± 3I7		
	53I5 ± 353	7.9 ± 3B	3.5 ± 3B		
	3.7 ± 13B	7.3± 3B	3.13± 3B		

Fig. 2: Length variation of 6 brands

Disintegration

The disintegration tests serve as a component in the overall quality control of capsule manufacturing. Disintegration test was conducted on the six different brands of cefixime 400mg capsule. In the present investigation all the six capsules of each brand showed disintegration within the range of 5.273 – 13.66 minutes (Fig. 3). The BP-2002 stipulates a disintegration time of not more than 15 min for uncoated tablets/capsules[16]. Product CEF-6 has shown a maximum average disintegration time about 13.66 ± 1.128 minutes and product code CEF-4 has shown minimum disintegration time about 5.273 ± 0.472 minutes, which is good as compared to other products because as early the tablet/capsule break as rapidly it goes under dissolution.


Fig. 3: Disintegration time for 6 different brands of cefixime capsules

Dissolution

Dissolution test is an extremely valuable tool in ensuring the quality of a drug product. Generally product-to-product variation is due to the formulation factors such as particle size, compression force, excessive amount of lubricant etc. Thus dissolution test are very effective in discriminating between and within batches of drug product(s). Dissolution testing is the most important way to study, under *in vitro* conditions, the release of a drug from a solid dosage form and thus represents an important tool to assess factors that affect the bioavailability of a drug from a solid preparation. It is not possible for any manufacturer to check the bioavailability of all batch of any product. In this situation the dissolution test acts as an important mean.

The present investigation showed that all the brands dissolved within limit (Table 3) and the statistical evaluation (ANOVA) of dissolution test indicated no significant variation between and within different brands of cefixime capsules (Table 4).

Table 3. Percent Dissolution (Mean + SD) of the six brands of Cefixime capsules

MuMMer of MMMsules	Percent of dissolution (%)					
	MMMM	MMMM	MMMM	MMMM	MMMM	MMMM
Cap7	7 7	7 7	7 7			
Cap7	7 7	7 7	7 7			
Cap7	7 7	7 7	7 7			
Cap7	7 7	7 7	7 7			
Cap7	7 7	7 7	7 7			
Cap7	7 7	7 7	7 7			
MeMn	7 7	7 7	7 7			
MMM	7 7	7 7 77				
MMM	7 7	7 7	7 7			

Table 4. ANOVA for percent of dissolution (%) of different brands of cefixime

| Source of Variation	SS		F	B		F	Fle	Rcrit	
Between Groups	5	5	5	5	5	5			
I I tl I n Groups	5	5	5						
I otl I	5	5							

Chemical Assay

The assay content of cefixime capsules (Table 5) showed that the active content of all the brands were between 95% and 105% of the label. The results indicated that although different manufacturers formulated different brands by different methods of formulation but all were under the BP/USP specifications. There were no significant difference in the release pattern of cefixime from different brands (Table 5), for the analysis of active content the method used was first developed and validated[18.] The precision and accuracy of the method is shown in Fig. 4a and 4b (standard and brand) indicates no interfering peak of excepient. Statistical analysis was also conducted using one-way analysis of variance (ANOVA). The statistical evaluation indicated that there was no significant variation between and within different brands of cefixime capsules (Table 6).

Table 5. Content assays of Cefixime capsules by HPLC

Assay	Cef-1	CEF-2	CEF-3	CEF-4	CEF-5	CEF-6
Assay-1	99.1%	102.33%	98.45%	101.6%	101.29%	99.22%
Assay-2	99.36%	101.82%	98.12%	104.08%	101.16%	99.03%
Assay-3	99.76%	102.27%	99.75%	101.03%	100.59%	98.44%
SUM	298.22	306.42	296.32	306.71	296.69	296.69
MEAN	99.40667	102.14	98.77333	102.237	101.0133	98.89667
S.D	0.332466	0.278747	0.861762	1.62161	0.372335	0.406735
SEM	0.135	0.113	0.351	0.662	0.152	0.166

Table 6. ANOVA single factor for content assay of Cefixime

Source of Variation	SS	df	MS	F	P-value	F crit
Between batches	26.36844	5	5.273688	4.869931	0.039888	4.387374
Within batch	6.49746	6	8.144803			
Total	32.86589	11				

(a)   Time (min)

(b)   Time (min)

**Fig. 4:** *a) Chromatogram of Standard*
b) Chromatogram of Sample

Antimicrobial Susceptibility Test

Resistance of common pathogens to Antimicrobial agents has emerged as one of the most important problems in the field of infectious diseases. As a matter of microbial evaluation of different brands of cefixime, broth micro-dilution method was employed against *E. coli* and *S. aureus.* The experiment was carried out on standardized cultures and isolates. The results were observed visually and spectrophotometrically (ë = 546nm). Among *E. coli*, the reported MIC for standard cefixime was in the range of 0.25-1ìg/ml against ATCC # 25922 that was observed in the same range [22]. Whereas the standard cefixime value against clinical isolates of *E. coli* has shown MICs ranging between 2 – 32 µg/ml (Fig: 5).

The MICs of different brands of cefixime against standard *E. coli*, ATCC # 25922 showed MICs ranging 1–2 µg/ml, five brands showed MICs of 1µg/ml and one brand showed MICs of 2µg/ml. The same brands were evaluated against clinical isolate of *E. coli* and showed MICs range of 8 – 64 µg/ml (Fig: 5).

Single factor ANOVA was applied on the MICs of cefixime reference and on different brands capsule against *E.coli.* The ANOVA showed insignificant variation of inhibitory concentration range among standard and brands of cefixime.

The comparison of MICs of different brands against standard and clinical isolate of *E. coli* is presented in Fig. 5. The increased MICs of cefixime against clinical isolates of *E. coli* indicates a budding of resistance of *E. coli* which is also in confirmation with the study conducted by Nakamura and Takahashi; 2004[23] and some other factors, that were related with the brands but the pharmaceutical parameters indicated brands to be in accordance to the official specifications.

Fig. 5: *Comparison of MICs against E. coli among standard and different brands.*

The reported MICs for standard cefixime was in the range of 4 – 64 µg/ml against *S. aureus* ATTC # 25922[24], which was observed in the same range. The MICs for standard cefixime against clinical isolates of *S. aureus* ranging between 8 –128 µg/ml. The MICs of different brands against standard *S. aureus* ranging between 8–32µg/ml, three brands showed MICs of 16µg/ml, one brand showed 8µg/ml and two brands showed of 32µg/ml (Fig: 6). The same brands were evaluated against clinical isolate of *S. aureus* and showed MICs range of 8 – 256 µg/ml (Fig: 6).

Fig. 6: Comparison of MICs against S. aureus among standard and different brands.

Single factor ANOVA was applied on the MICs of cefixime against *S. aureus*. This analysis indicated that there was no significant change of inhibitory concentration range. The increase in the MICs of cefixime against different clinical isolates of *S. aureus* indicated a growing of resistance in *S. aureus*. The present results are in confirmation with work of Soussy et al in 1989[25].

DISCUSSION

The specification for pharmaceutical capsule usually includes appearance, weight, length and diameter, disintegration, dissolution, and content assay etc. These specifications are established to ensure that the capsule will have sufficient mechanical strength to withstand packaging, shipping, and handling and are physically and chemically stable to deliver the accurate amount of drug at the desired dissolution rate when consumed by a patient. Any changes in these characteristics may significantly affect the safety and efficacy of the product. Therefore it is very important to keep a check on each and every step during the formulation and manufacturing of a drug product. There are a number of scientists who also evaluated the efficacy and safety of different brands and dosage form of drug which contain cefixime[26-30] and suggested that these are well tolerated in terms of safety. But none of them evaluated the efficacy and potency of different brands of cefixime in Pakistani environment. Whereas, the Asians have quite different ecological and sociological circumstances and different body physiology, diet habits and economical conditions as compared to others that can produce significant effects on the absorption behavior (bioavailability) of the drug. Table 5 shows the mean percentage of stated content obtained for each of the 6 brands of capsules. All brands met pharmacopoeial specifications with regard to content of active ingredient. All brands passed the dissolution test for the release of cefixime (Table 3). The percentage of cefixime released within 45 minutes was in the range 95.5983 -99.04, which once again was in conformity with USP monograph that requires an amount not less than 80% of the labeled amount of the drug to be released into the medium at 45 minute. In the present study the brand CEF # 6 has shown all the six capsules dissolved within 15minutes but its time of disintegration is greater than all the other five brands that disintegrated within 13.66 minutes (Fig.3).

The antimicrobial action of the different studied brands of cefixime has shown positive results with the required MICs, this result emphasizes on the rationale use of antibiotics in order to keep the efficacy of the antimicrobial agent without causing resistance.

A number of research articles[26-30] are available which indicates that the physicochemical parameter's evaluation of different drug substances are required for the achievement of a stable and effective product which may be pharmaceutically equivalent whether the drug is bioequivalent or not in vivo, but to know that if the drug is pharmaceutically equivalent, initially its physicochemical parameters are needed to be evaluated.

There are many researches that emphasize the need to evaluate different brands of the same generic drug in order to screen the quality product available in local market[7, 31-33].

REFERENCES

1.   Abu-Reid IO, et al., Pharmacy J. 1990; 4: 6.

2.   Dennis P, et al., Pharmacy J. 1992; 6: 64.

3.   Kibwage IO, et al., East African Med J. 1992; 69: 577.

4.   Murtada M, Sesay B. Pharmacy J. 1994; 8: 202.

5.   Covington TR. Clin Res Reg Affairs. 1992; 9: 103.

6.   Shah HK. Persp Pharm Eco. 1992; 4:3.

7.   Michael A Odeniyi, et.al., Trop J Pharm Res. 2003; 2:161.

8.   World Health Organization. "Expert Committee on specifications for Pharmaceutical Preparations". 34th Report WHO Technical Report. Series No. 863, Geneva, Switzerland: WHO 1996; p.114.

9.   Itiola OA, et al., Pharmazie. 1996; 51: 987.

10.   Wilson and Gisvold's Text book of organic and medicinal and pharmaceutical chemistry. 10th Edition, London. 1998; p. 287.

11.   Wu DH. Clin Ther. 1993; 15: 1108.

12.   Sakane K, et.al., Yakugaku Zasshi. 1993; 113: 605.

13. Roche G. Presse Med. 1989; 18: 1541.

14. Memon IA, et al., South Med J. 1997; 90: 1204.

15. Edward Rudnic. Oral solid dosage forms, In : *"Remington"* The science and practice of pharmacy. Mack Publishing Company. Easton, Pennsylvania. 1995; p.1642.

16. British Pharmacopoeia. 2002; Appendix: XII, p. H A2-53.

17. United State Pharmacopeia 27. 2004 p. 2622.

18. Hafiz MA, et al., Jordan J Pharm Sci. 2009; 2: 55.

19. Rammel kamp CH, et al., Proc Soc Exp Boil Med.1942; 51:386.

20. Shakoor O, et al., Trop Med Int Health. 1997; 2: 839.

21. Arya SC. Lancet. 1997; 350: 1106.

22. Memon IA, et al., South Med J. 1997; 90: 1204.

23. Nakamura T, et al., Jpn J Antibiot. 2004; 57: 465.

24. McAteer JA, et al., Clin Chem. 1987; 33:1788.

25. Soussy CJ, et al., J Presse Med. 1989; 18:1546.

26. Boudignat O, et al., Presse Med. 1989; 18:1622.

27. Counts GW, et al., Eur J Clin Microbiol Infect Dis. 1988; 7: 428.

28. Fass RJ, et al., Chemioterapia. 1988; 7: 365.

29. Kees F,et al., Arzneimittelforschung. 1990; 40: 293.

30. Sakata T, et al., Hinyokika Kiyo. 1992; 38: 1337.

31. Mittapalli PA, et al., AAPS PharmSciTech. 2008; 9: 1530.

32. Bamiro OA, et al., J Hosp Med. 2007; 17: 22.

33. G Kahsay, et al., Ethiop Pharm J. 2007;25:1.